FDA Approves Atripla, Once Daily Single Tablet AIDS Drug
Filed in archive Drugs, Vaccines and Therapeutics on July 14, 2006
The US Food and Drug Administration has approved of the new once-a-day, three-in-one AIDS pill. The drug, called Atripla, was jointly developed by Bristol-Myers Squibb Co and Gilead, Inc, and combines the powers of the commonly prescribed AIDS drugs Sustiva, Viread and Emtriva in one pill, The drug inhibits the Reverse transcriptase, an enzyme HIV needs to replicate.
Certainly not a real breakthrough, but might mean more compliance from AIDS patients. According to the manufacturers, Atripla will cost $1,150.88 for a 30-day supply. No price has been set for developing countries. A similar three-in-one AIDS pill produced by India-based Aurobindo Pharma has also been previously approved. However, this version, which is not sold in the US, contains generic versions of older HIV drugs.
More details from Reuters and from the press releases from Gilead and BMS.

Tags: AIDS HIV aids biotech drug aids+drug approves+atripla single+tablet
Vote for FDA Approves Atripla, Once Daily Single Tablet AIDS Drug:
|
Rating: 6.14 out of 7 vote(s) cast.
|
Response from:
Generic Atripla
(05/13/10 7:58am)
This article is a great snapshot of the excitement over this combo-pill when it first hit the market. However it missed that Aurbindo wasn't the only generic manufacturer to create a combo pill. Cipla produced Viraday, and Emcure produced Vonavir. For a complete listing of HIV generics from india, please see: http://www.aids-drugs-online.com/antivirals.php
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
